Hypoimmune Pluripotent Cells for Universal Regenerative Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current regenerative cell therapies face significant challenges due to the propensity for immune rejection of transplanted cells, particularly those with mismatched HLA and blood group antigens, which limits their efficacy and applicability.
Innovation Solution
Development of hypoimmune pluripotent cells (HIPO− cells) with reduced expression of HLA-I and HLA-II and increased expression of CD47, specifically engineered to be ABO blood type O and Rhesus Factor negative, thereby minimizing immune rejection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If allogeneic pluripotent stem cells are used for regenerative cell therapy, then cell availability and manufacturing efficiency are improved, but immune rejection risk increases
Solution Approach 1:
The patent applies parameter changes by modifying the immunogenic parameters of pluripotent stem cells through genetic engineering. Specifically, HLA class I and class II genes are knocked out to eliminate antigen presentation, and CD47 is overexpressed to enhance immune evasion. These parameter modifications transform standard allogeneic cells into hypoimmunogenic cells that can be used universally without immune rejection, resolving the contradiction between cell availability and immune compatibility.
Solution Approach 2:
The patent creates a composite cellular structure by combining multiple genetic modifications within the same cell line. The cells contain both HLA knockout modifications (to reduce immunogenicity) and CD47 overexpression (to enhance immune evasion). This composite genetic profile produces cells with superior hypoimmunogenic properties that overcome the limitations of standard allogeneic cells.
2Reliability
If HLA-matched pluripotent stem cells are used, then immune compatibility is improved, but manufacturing complexity and time increase
Solution Approach 1:
The patent achieves universality by creating a single hypoimmunogenic cell line that can be used for any patient without requiring HLA matching. The genetic modifications (HLA knockout and CD47 overexpression) confer broad immune evasion capabilities that make the cells universally compatible across different recipients. This eliminates the need for complex HLA typing, matching, and individualized cell manufacturing processes.
3Speed
If standard pluripotent stem cells are transplanted, then treatment speed is improved, but long-term cell survival decreases due to immune rejection
Solution Approach 1:
The patent applies preliminary action by pre-modifying the immunogenic properties of pluripotent stem cells before transplantation. The HLA knockout and CD47 overexpression are performed during cell culture and quality control phases, allowing the hypoimmunogenic characteristics to be established prior to clinical use. This preliminary genetic engineering ensures that cells can be rapidly administered without immune rejection while maintaining long-term survival and engraftment.
Data Source
AI summary
The invention discloses for the first time pluripotent cells, including induced pluripotent stem cells, embryonic stem cells, hypo-immune pluripotent cells, cells that have been derived therefrom, and cells that have been biologically differentiated therefrom into particular tissue lineages that are ABO blood type O Rhesus Factor negative or otherwise evade rejection resulting from blood type antigen mismatch. The invention further provides universally acceptable “off-the-shelf” pluripotent cells and derivatives thereof for generating or regenerating specific tissues and organs.